MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Endocrine resistance and metastatic progression are primary causes of treatment failure in breast cancer. While mitogen activated protein kinases (MAPKs) are known to promote ligand-independent cell growth, the role of the MEK5-ERK5 pathway in the progression of clinical breast carcinoma remains poo...
Main Authors: | James W Antoon, Elizabeth C Martin, Rongye Lai, Virgilo A Salvo, Yan Tang, Ashley M Nitzchke, Steven Elliott, Seung Yoon Nam, Wei Xiong, Lyndsay V Rhodes, Bridgette Collins-Burow, Odile David, Guandi Wang, Bin Shan, Barbara S Beckman, Kenneth P Nephew, Matthew E Burow |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3739787?pdf=render |
Similar Items
-
Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation
by: Adrienne K. Conger, et al.
Published: (2016-09-01) -
Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk
by: Beckman Barbara S, et al.
Published: (2010-11-01) -
ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer
by: Van T. Hoang, et al.
Published: (2020-08-01) -
The MEK5/ERK5 Pathway in Health and Disease
by: Rupesh Paudel, et al.
Published: (2021-07-01) -
Pathophysiological Impact of the MEK5/ERK5 Pathway in Oxidative Stress
by: Ignazia Tusa, et al.
Published: (2023-04-01)